Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
ARK Invest Boosts Gene-Editing Bets While Cutting Consumer Tech Exposure
12:23pm, Monday, 05'th Jan 2026
Cathie Wood's ARK Invest is entering 2026 with a noticeably sharper bet on early-stage biotechnology, while selectively reducing exposure to consumer technology
Can BEAM's Gene Editing Pipeline Create Long-Term Value Amid Rivalry?
10:35am, Wednesday, 31'st Dec 2025
Beam Therapeutics advances base-editing pipeline with risto-cel studies and FDA designations, but no approved products and rising competition loom.
Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab
06:26am, Wednesday, 31'st Dec 2025
Cathie Wood's ARK Invest made a series of end-of-year portfolio adjustments on the second final trading day of 2025, tilting further toward biotechnology while
TSLA: Cathie Wood Dumps $30 Million Worth Tesla Stock
12:51pm, Monday, 29'th Dec 2025
Cathie Wood's Ark Invest increased stakes in gene-editing and autonomous mobility companies while trimming holdings in Tesla (TSLA) and Rocket Lab (RKLB).Sellin
Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
04:01pm, Thursday, 18'th Dec 2025
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Joh
Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Show Mean He moglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to
38,438 Shares in Beam Therapeutics Inc. $BEAM Purchased by Capital Fund Management S.A.
03:58am, Saturday, 06'th Dec 2025
Capital Fund Management S.A. acquired a new stake in shares of Beam Therapeutics Inc. (NASDAQ: BEAM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Com
Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal
02:39pm, Thursday, 04'th Dec 2025
Beam Therapeutics Inc. remains a Strong Buy, supported by robust BEAM-101 phase 1/2 BEACON trial data in sickle cell disease. BEAM-101 consistently achieved >60% Hemoglobin F induction,
Why Is Beam Therapeutics (BEAM) Up 15.9% Since Last Earnings Report?
12:30pm, Thursday, 04'th Dec 2025
Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock?
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
09:15am, Thursday, 27'th Nov 2025
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
07:00am, Wednesday, 12'th Nov 2025
CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that man
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Lags Revenue Estimates
09:37am, Tuesday, 04'th Nov 2025
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.1 per share versus the Zacks Consensus Estimate of a loss of $0.98. This compares to a loss of $1.17 per share a year ago.
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
07:00am, Tuesday, 04'th Nov 2025
Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin Deficiency Ongoing; Updated Data and Clinical Development Update Expected in Early
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
Beam Therapeutics (BEAM) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
10:55am, Wednesday, 29'th Oct 2025
Beam Therapeutics (BEAM) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could
